Compare AMS & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMS | MTNB |
|---|---|---|
| Founded | 1980 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 5.2M |
| IPO Year | 1995 | 2014 |
| Metric | AMS | MTNB |
|---|---|---|
| Price | $1.50 | $0.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.0K | ★ 5.7M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,714,000.00 | $119,750.00 |
| Revenue This Year | $6.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $1.25 | $0.23 |
| 52 Week High | $3.11 | $2.24 |
| Indicator | AMS | MTNB |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 33.89 |
| Support Level | $1.37 | $0.23 |
| Resistance Level | $1.75 | $0.65 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 27.78 | 8.42 |
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. Company operates in two segments, the medical equipment leasing segment where a contract exists between the hospital and the Company and the direct patient services segment, where a contract exists between the Company facilities and the individual treated at the facility. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates it's key revenue from the domestic market.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.